DiaGen AI / Decentralized science
DiaGen is among the first drug discovery companies to move into blockchain-based decentralized AI.
Why the triad works
Many DeSci efforts lack either real science or real infrastructure. The strategy here is materially stronger because each partner occupies a distinct layer of the value chain rather than competing for the same one.
DeSci partner · JV LOI
A crypto-native biotech built directly on Bittensor, operating a decentralized drug screening subnet (SN68). Co-development partner on a multi-objective hit-picking tool that evaluates small molecules for novelty, affinity and target specificity across multi-million to billion-scale libraries.
Also the benchmarking counterparty for DiaGen's generative models in an open, incentive-driven environment. Both parties contribute models, validators and datasets — but proprietary models stay proprietary.
DeSci partner · JV announced
A web3-native venture and ecosystem builder focused on decentralized AI and blockchain infrastructure, active across 100+ projects. CEO Mike Grantis serves as strategic advisor to DiaGen on decentralized initiatives, supporting Bittensor subnet participation, validator and miner strategy, and token economics.
$100K committed capex toward decentralized compute, with $40K deployed to date.
Combined architecture
Distributed compute and open competition shift cost from fixed, infrastructure-heavy spend to variable and performance-based — while benchmarking against decentralized competitors introduces market-based validation rather than internal metrics, which matters most where ground truth is sparse.
For platform access, catalog partnering or co-development enquiries.
IR@diagen.ai